Related Experiment Video
Updated: Jun 8, 2026
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Recent advances in managing triple-negative breast cancers
1Division of Medical Oncology, Department of Oncology, Hematology and Respiratory Diseases, University Hospital, University of Modena and Reggio Emilia Via del Pozzo, 71 - 41100, Modena Italy.
F1000 Medicine Reports
|October 16, 2010
Summary
Triple-negative breast cancer (TNBC) lacks specific targets, making conventional chemotherapy the primary treatment. This review covers current management strategies and recent advancements for TNBC.
Area of Science:
- Oncology
- Medical Research
Background:
- Triple-negative breast cancer (TNBC) is a distinct breast cancer subtype.
- TNBC lacks expression of estrogen receptors, progesterone receptors, and HER2.
- This necessitates different therapeutic strategies compared to other breast cancer types.
Purpose of the Study:
- To review the current management of TNBC.
- To highlight recent advances in TNBC treatment.
Main Methods:
- Literature review of current clinical practices.
- Analysis of recent research findings and clinical trials.
Main Results:
- Conventional cytotoxic chemotherapy remains the primary treatment modality for TNBC.
- Emerging therapeutic approaches are being investigated and developed.
Conclusions:
- Effective management of TNBC requires understanding its unique characteristics.
- Continued research is crucial for improving outcomes in triple-negative breast cancer.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...